Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Jun Zhao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7739-6715; OpenAlex author ID A5029786366, A5123375341. Sources: OpenAlex.

Their work

Papers
22 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
103
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: 2 papers · 2019: 4 papers · 2020: 2 papers · 2021: 3 papers · 2022: 5 papers · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 22

  1. Disruption of iron homeostasis sensitizes pancreatic cancer to irreversible electroporation. Last author DOI 10.1038/s41467-026-68585-z↗
  2. Co-inhibition of RAGE and TLR4 sensitizes pancreatic cancer to irreversible electroporation in mice by disrupting autophagy. Last author DOI 10.1038/s41401-025-01487-w↗
  3. Irreversible Electroporation-Induced Inflammation Facilitates Neutrophil-Mediated Drug Delivery to Enhance Pancreatic Cancer Therapy. Co-author DOI 10.1021/acs.molpharmaceut.4c00006↗
  4. Nardilysin-regulated scission mechanism activates polo-like kinase 3 to suppress the development of pancreatic cancer. Co-author DOI 10.1038/s41467-024-47242-3↗
  5. Simultaneous Delivery of Dual Inhibitors of DNA Damage Repair Sensitizes Pancreatic Cancer Response to Irreversible Electroporation. Last author DOI 10.1021/acsnano.3c05009↗
  6. Local Release of TGF-β Inhibitor Modulates Tumor-Associated Neutrophils and Enhances Pancreatic Cancer Response to Combined Irreversible Electroporation and Im… Last author DOI 10.1002/advs.202105240↗
  7. Single-cell analysis reveals nanosecond pulsed electric field ablation induced myeloid cells remodeling in pancreatic cancer. Co-author DOI 10.1016/j.bioelechem.2022.108266↗
  8. Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment. Co-author DOI 10.1053/j.gastro.2022.02.024↗
  9. Safety and Efficacy of Irreversible Electroporation in Locally Advanced Pancreatic Cancer: An Evaluation from a Surgeon's Perspective. Co-author DOI 10.3390/cancers14225677↗
  10. Targeting the alterations of ARID1A in pancreatic cancer: tumorigenesis, prediction of treatment, and prognostic value. Co-author PMID 36247295↗
  11. Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival. Co-author DOI 10.1016/j.pan.2021.03.018↗
  12. PTHrP Drives Pancreatic Cancer Growth and Metastasis and Reveals a New Therapeutic Vulnerability. Co-author DOI 10.1158/2159-8290.cd-20-1098↗
  13. Pancreatic Cancer-Related Mutational Burden Is Not Increased in a Patient Cohort With Clinically Severe Chronic Pancreatitis. Co-author DOI 10.14309/ctg.0000000000000431↗
  14. Significance of Cancer Cells at the Vein Edge in Patients with Pancreatic Adenocarcinoma Following Pancreatectomy with Vein Resection. Co-author DOI 10.1007/s11605-019-04126-y↗
  15. Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC): A Multi-Institutional Study. Co-author DOI 10.3390/cancers12123656↗
  16. Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer. Co-author DOI 10.1038/s41467-019-08782-1↗
  17. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2018.09.022↗
  18. Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progre… Co-author DOI 10.1158/1078-0432.ccr-18-1955↗
  19. YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci.insight.130811↗
  20. Simultaneous inhibition of hedgehog signaling and tumor proliferation remodels stroma and enhances pancreatic cancer therapy. Co-author DOI 10.1016/j.biomaterials.2018.01.014↗
  21. Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer. Co-author DOI 10.1021/acsnano.8b02481↗
  22. Cyclopamine-loaded core-cross-linked polymeric micelles enhance radiation response in pancreatic cancer and pancreatic stellate cells. Co-author DOI 10.1021/mp500875f↗

Closest collaborators

The 25 strongest of 103 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xin Long · 5 shared papers, 2022–2026 · strength 1.12
  2. Anirban Maitra · 9 shared papers, 2018–2024 · strength 0.84
  3. Huamin Wang · 6 shared papers, 2018–2024 · strength 0.60
  4. Chun Li · 6 shared papers, 2015–2023 · strength 0.60
  5. Tianan Jiang · 3 shared papers, 2022–2025 · strength 0.59
  6. Teng Huang · 3 shared papers, 2022–2024 · strength 0.56
  7. Matthew H. G. Katz · 5 shared papers, 2019–2021 · strength 0.46
  8. Michael P. Kim · 4 shared papers, 2019–2021 · strength 0.37
  9. Jian Shen · 2 shared papers, 2022 · strength 0.34
  10. Heshui Wu · 2 shared papers, 2022 · strength 0.34
  11. Ching-Wei David Tzeng · 3 shared papers, 2019–2021 · strength 0.30
  12. Linrong Li · 1 shared paper, 2026 · strength 0.30
  13. Tao Yin · 1 shared paper, 2026 · strength 0.30
  14. Hui Xu · 2 shared papers, 2022–2023 · strength 0.30
  15. Ya’an Kang · 3 shared papers, 2018–2024 · strength 0.28
  16. Jason B. Fleming · 3 shared papers, 2018–2024 · strength 0.28
  17. Robert A. Wolff · 3 shared papers, 2019–2021 · strength 0.28
  18. Cuifang Ye · 1 shared paper, 2025 · strength 0.27
  19. Vincent Bernard · 3 shared papers, 2019–2022 · strength 0.26
  20. Cullen M. Taniguchi · 3 shared papers, 2019–2022 · strength 0.26
  21. Laura R. Prakash · 2 shared papers, 2020–2021 · strength 0.23
  22. Jeffrey E. Lee · 2 shared papers, 2020–2021 · strength 0.23
  23. Eugene Jon Koay · 3 shared papers, 2018–2020 · strength 0.23
  24. Guangbing Xiong · 1 shared paper, 2022 · strength 0.22
  25. Ruichao Li · 1 shared paper, 2022 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.